Level Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Level Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$252K	Sell	4,200 -2,680	-39%	-$169K	0.1%	75
2026 Q2	$394K	Hold	6,880	–	–	0.16%	48
2026 Q1	$389K	Hold	6,880	–	–	0.18%	41
2025 Q4	$409K	Sell	6,880 -2,180	-24%	-$119K	0.21%	36
2025 Q3	$491K	Hold	9,060	–	–	0.26%	32
2025 Q2	$498K	Hold	9,060	–	–	0.29%	31
2025 Q1	$640K	Sell	9,060 -483	-5%	-$32.5K	0.42%	22
2024 Q4	$627K	Buy	+9,543	New	+$639K	0.44%	24

Other funds holding BMRN

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Covea Finance Paris, France $3.07B AUM 27.46% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Level Wealth Management's BMRN Position: Q3 2026 in Review

Level Wealth Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 39% in Q3 2026, selling an estimated $169K and leaving 4,200 shares worth $252K. The position accounts for 0.1% of the portfolio, ranked #75.

Level Wealth Management first reported a position in BMRN in Q4 2024 and has held it in 8 quarters since. The position peaked at $640K in Q1 2025. 143 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

Level Wealth Management held 4,200 shares of BioMarin Pharmaceuticals worth $252K as of Q3 2026.
Level Wealth Management sold 2,680 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $169K.
BioMarin Pharmaceuticals made up 0.1% of Level Wealth Management's portfolio in Q3 2026, its #75 holding.
Level Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
Level Wealth Management's BioMarin Pharmaceuticals position peaked at $640K in Q1 2025.
143 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Level Wealth Management's 13F filing for Q3 2026, filed 23 Oct 2026.